Views: 295 Author: ZHENYIBIO Publish Time: 2026-10-27 Origin: Site
Content Menu
● COA vs. TDS vs. SDS: Key Differences at a Glance
● What Is a COA for Cosmetic Ingredients?
>> What Should Buyers Check on a COA?
>> Representative COA vs. Actual Batch COA
● What Is a TDS for Cosmetic Ingredients?
>> Information a Useful TDS Should Explain
>> Typical Values Are Not Release Specifications
● What Is an SDS for Cosmetic Ingredients?
>> Which SDS Sections Matter Most to Buyers?
>> Does Every Cosmetic Raw Material Legally Require an SDS?
● Which Documents Do Cosmetic Ingredient Buyers Need at Each Stage?
● Botanical and Fermented Actives: Additional Questions Buyers Should Ask
>> Botanical Extracts: Identify More Than the Plant Name
>> Fermentation-Derived Ingredients: Clarify What Is Being Supplied
● A Practical Cross-Document Audit Before Purchase
>> Step 1: Match Identity Across the Documents
>> Step 2: Reconcile Specifications and Composition
>> Step 3: Resolve Storage and Shelf-Life Conflicts
>> Step 4: Record Approval and Change Controls
● Illustrative Case: Why Matching Assay Numbers Can Mislead
● Why COA, TDS, and SDS Are Not a Complete Compliance Package
● Start Your ZHENYIBIO Ingredient Inquiry with a Document Checklist
>> Is a TDS the Same as a Specification Sheet?
>> Should Every Shipment Have a New COA?
>> Does "Not Classified as Hazardous" Mean Safe for Every Cosmetic Use?
>> How Often Should an SDS Be Updated?
>> Does a Passing COA Prove an Ingredient Works?
When comparing COA vs. TDS vs. SDS, cosmetic ingredient buyers should normally request all three during supplier qualification, while recognizing that SDS obligations depend on the material and destination market. A Certificate of Analysis verifies a specific batch against specifications. A Technical Data Sheet explains an ingredient's characteristics and formulation guidance. A Safety Data Sheet communicates chemical hazards and safe handling.
These documents serve different decisions. None replaces the others, and together they still do not constitute a complete cosmetic safety or regulatory dossier.
For botanical extracts and fermentation-derived actives, the distinction is particularly important. A promising ingredient description cannot establish batch consistency, and a passing laboratory result cannot explain formulation compatibility.
My recommended purchasing principle is traceability: connect the ingredient you evaluate, the specification you approve, and the batch you receive.
| Comparison point | COA | TDS | SDS |
|---|---|---|---|
| Full name | Certificate of Analysis | Technical Data Sheet | Safety Data Sheet |
| Primary purpose | Document batch conformity | Describe technical characteristics and applications | Communicate hazards and protective measures |
| Main question | Does this batch meet agreed specifications? | Is this ingredient suitable for our formulation? | How should we handle this material safely? |
| Typical content | Lot number, specifications, results, dates, authorization | Ingredient identity, properties, recommended use, processing and storage guidance | Hazard classification, first aid, handling, exposure controls, emergency information |
| Batch-specific? | Normally yes | Usually no | Usually no |
| Main users | Quality control and purchasing | Formulators and technical buyers | Safety teams, warehouse staff, logistics personnel |
| Update trigger | Each released batch | Relevant product or technical changes | Relevant hazard, composition, or regulatory changes |
A practical sequence is to review the TDS during ingredient selection, the SDS before handling samples, and the actual batch COA before accepting production material.
A Certificate of Analysis records whether an identified batch meets specified quality requirements. It should connect the supplied material to an approved specification and a documented release decision.
Request the following, as applicable:
- Product name, grade, and supplier product code.
- Batch or lot number matching the container label.
- Manufacturing date and expiry or retest date.
- Tests, acceptance limits, and results.
- Test methods or identifiable method references.
- Issue date and authorized release identification.
For important quantitative parameters, numerical results provide more purchasing value than an unexplained "Pass." However, qualitative tests may appropriately report "Conforms."
Also clarify whether each result comes from batch testing, periodic verification, or another justified quality-control arrangement. A COA should not leave buyers guessing about the evidence behind release.
A representative COA helps buyers assess a supplier's testing format before ordering. It does not establish the quality of an incoming shipment.
Public supplier examples explicitly identify some downloadable certificates as representative samples and note that results may vary between lots.
Before production use, obtain the certificate associated with the actual supplied batch. A matching product name without a matching lot number is insufficient for batch verification.
A Technical Data Sheet describes an ingredient's technical profile and intended applications. Unlike an SDS, its format is generally supplier-defined.
Think of it as a starting point for formulation development—not a guarantee that the ingredient will perform identically in every finished product.
Depending on the ingredient, look for:
- INCI identification and product form.
- Functional role and intended applications.
- Solubility or dispersibility.
- Suggested incorporation level.
- Recommended processing conditions.
- Relevant pH and temperature guidance.
- Storage conditions and shelf-life information.
- Compatibility limitations and supporting technical data.
A suggested use level is not automatically a legal maximum or a demonstrated safe concentration in every application.
Similarly, "water-soluble" needs context. Ask whether the statement describes the complete commercial blend, the active fraction, or performance under particular test conditions.
A TDS may report a typical pH, color, or active content. Those values can describe expected characteristics without establishing contractual acceptance limits.
Before ordering, separate three categories:
1. Typical properties.
2. Guaranteed specifications.
3. Application recommendations.
This distinction prevents disputes when a delivered batch differs from a typical value but still meets the approved specification.
A Safety Data Sheet communicates chemical hazards, exposure precautions, emergency measures, and other safe-use information.
It is not a certificate of cosmetic efficacy, purity, or finished-product safety.
The familiar SDS structure contains 16 section headings. Buyers should prioritize:
- Sections 1–3: identification, hazards, and composition.
- Sections 4–6: first aid, firefighting, and spill response.
- Sections 7–8: handling, storage, and exposure controls.
- Sections 9–11: properties, reactivity, and toxicological information.
- Sections 14–16: transport, regulatory information, and revision details.
Requirements vary by jurisdiction. Under the U.S. OSHA framework, Sections 1–11 and 16 contain mandatory information; Sections 12–15 are not mandatory under OSHA.
An SDS composition section is also not necessarily a complete cosmetic labeling declaration. Obtain appropriate ingredient-composition information separately.
No universal rule applies to every ingredient in every market.
Under EU REACH, SDS requirements cover specified situations, including hazardous substances or mixtures, certain substances of concern, and some nonhazardous mixtures when requested.
Where an SDS is not required, suppliers must still provide sufficient safe-use information.
For procurement, request an SDS or a clear explanation of its applicability. "Natural" should never substitute for a documented hazard assessment.
The most useful approach matches documents to purchasing decisions rather than collecting files without reviewing them.
| Purchasing stage | Documents to request | Decision supported |
|---|---|---|
| Initial screening | TDS and preliminary specifications | Technical suitability |
| Sample evaluation | SDS or applicable safe-use information; sample COA | Safe handling and sample identity |
| Supplier approval | Approved specifications, representative COA, relevant supporting evidence | Qualification |
| Commercial receipt | Actual batch COA and current applicable technical documents | Acceptance or quarantine |
| OEM/ODM development | Ingredient dossier plus formula-specific supporting information | Development and finished-product assessment |
| Change review | Revised documents and change-impact explanation | Continued suitability |
Brands need information supporting finished-product decisions. Wholesalers need document continuity across the supply chain. Manufacturers need usable specifications and handling instructions.
An OEM/ODM agreement should identify who supplies, reviews, updates, and retains each document.
For a manufacturer such as ZHENYIBIO TECHNOLOGY INC, combining botanical materials with biofermentation makes ingredient identity and process transparency especially relevant.
Ask the supplier to clarify:
- Botanical identity and plant part.
- Extraction solvent and commercial carrier.
- Relevant marker compounds.
- Assay basis and analytical method.
- Risk-based contaminant controls.
- Preservatives or other intentionally added components.
A standardized marker assay supports compositional consistency. It does not, by itself, prove a finished-product skincare benefit.
Contaminant testing should reflect the ingredient, sourcing conditions, process, intended application, and target market—not a universal checklist presented as mandatory everywhere.
"Fermented botanical active" can describe materially different products.
Ask whether the commercial ingredient is a filtrate, lysate, purified metabolite, or blend. Clarify carrier composition, preservation, relevant residuals, and storage requirements.
Where identity or safety assessment requires further process details, arrange appropriate technical disclosure, potentially under confidentiality.
Fermentation alone does not establish superior efficacy, lower environmental impact, or better tolerability. Each claim needs evidence relevant to the actual ingredient.
My recommended review starts with consistency, not document appearance.
Compare the trade name, grade, product code, supplier, and relevant identifiers.
Investigate differences. Similar names can conceal different concentrations, carriers, or product forms.
Check whether the COA limits match the approved specification. Compare the TDS description with available composition information and the SDS.
Differences are not automatically errors: these documents have different disclosure purposes. However, unexplained contradictions require clarification.
If one document recommends refrigeration while another specifies room-temperature storage, request written clarification.
Also distinguish an expiry date from a retest date. They support different quality decisions.
Assign responsibility for technical approval, safety review, and incoming release.
Agree which changes require notification, including changes to composition, process, specifications, test methods, or manufacturing location.
Consider two hypothetical botanical powders, each described as containing "10% marker compound."
Supplier A reports the assay on a dry basis. Supplier B reports it on an as-supplied basis.
If Supplier A's powder contains 5% moisture, a 10% dry-basis assay corresponds to approximately 9.5% marker in the supplied material.
The headline values therefore are not directly equivalent.
This illustrative calculation is not ZHENYIBIO product data. It demonstrates why buyers should compare assay basis, moisture, method, and commercial form before comparing price per kilogram.
Even identical marker concentrations would not establish equivalent biological performance.
These documents support ingredient assessment. They do not independently establish that a finished cosmetic is safe, compliant, stable, or effective.
For U.S. cosmetics, MoCRA requires the responsible person to ensure and maintain records supporting adequate safety substantiation. Neither the law nor FDA regulations prescribe one specific test package for every ingredient or product.
Depending on the project, additional evidence may include:
- Relevant toxicological information and exposure assessment.
- Stability and packaging-compatibility testing.
- Microbiological quality and preservation assessment.
- Composition information for labeling and regulatory review.
- Studies supporting intended product claims.
- Documentation supporting specific sustainability statements.
For efficacy claims, distinguish laboratory findings, ingredient studies, and finished-formula studies. They answer different questions and should not be presented as interchangeable.
For a botanical active, fermentation-derived ingredient, or OEM/ODM project, send ZHENYIBIO TECHNOLOGY INC your target market, intended application, required ingredient profile, and purchasing volume.
Request the relevant TDS, applicable SDS or safe-use information, representative COA, and proposed release specifications. Confirm actual batch COA requirements before shipment.
Ask which efficacy, safety, and sustainability documents are available for the specific material. Identify any additional development or testing needs before commercial approval.
No. An SDS communicates hazards and safe handling. A COA documents conformity of an identified batch against specifications. Neither performs the other's function.
Not necessarily. A TDS often includes typical properties and application guidance. A specification sheet defines acceptance criteria. Suppliers may combine them, so confirm which values are guaranteed.
Obtain a COA for every supplied batch. One shipment containing several batches requires corresponding certificates. Separate shipments from the same batch may reference the same valid certificate.
No. Hazard classification does not establish safety at every concentration, exposure pattern, or application site. Finished-product assessment must consider actual conditions of use.
There is no universally applicable annual expiry rule. Relevant new hazard information or risk-management requirements can trigger updates. Check the revision date and obtain confirmation that the document remains current.
No. It supports conformity with the listed specifications. Efficacy requires appropriate evidence, and ingredient-level findings do not automatically substantiate claims for a finished formula.
1. Occupational Safety and Health Administration. [Hazard Communication—Appendix D: Safety Data Sheets]. Primary requirements covering SDS information and section-specific obligations. [osha]
2. European Chemicals Agency. [Extended Safety Data Sheets]. Guidance on SDS supply conditions, updates, downstream-user responsibilities, and information where an SDS is not required. [echa.europa]
3. U.S. Food and Drug Administration. [Modernization of Cosmetics Regulation Act of 2022]. Primary explanation of cosmetic safety-substantiation responsibilities. [fda]
4. MakingCosmetics. [Galactoarabinan—Representative Certificate of Analysis]. Commercial example showing specifications, results, an anhydrous assay basis, and representative-certificate limitations. [makingcosmetics]
5. MakingCosmetics. [Lanolin Wax—Representative Certificate of Analysis]. Commercial example illustrating test methods, acceptance limits, numerical results, and conformity decisions. [makingcosmetics]
